Total Payments
$985.48
2023 Payments
$63.36
Companies
14
Transactions
32
Medicare Patients
1,182
Medicare Billing
$261,765
Payment Breakdown by Category
Food & Beverage$917.49 (93.1%)
Education$67.99 (6.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $917.49 | 31 | 93.1% |
| Education | $67.99 | 1 | 6.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $271.92 | 6 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $158.55 | 3 | $0 (2022) |
| Merck Sharp & Dohme Corporation | $141.52 | 2 | $0 (2018) |
| Incyte Corporation | $136.52 | 5 | $0 (2022) |
| Janssen Biotech, Inc. | $86.51 | 5 | $0 (2023) |
| Celgene Corporation | $55.94 | 3 | $0 (2023) |
| Ipsen Biopharmaceuticals, Inc | $25.30 | 1 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $18.60 | 1 | $0 (2022) |
| Amgen Inc. | $17.14 | 1 | $0 (2022) |
| Seagen Inc. | $15.73 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $63.36 | 3 | Ipsen Biopharmaceuticals, Inc ($25.30) |
| 2022 | $221.21 | 12 | Janssen Biotech, Inc. ($54.51) |
| 2021 | $230.70 | 6 | Genentech USA, Inc. ($101.66) |
| 2019 | $203.96 | 6 | Novartis Pharmaceuticals Corporation ($125.00) |
| 2018 | $16.52 | 1 | Merck Sharp & Dohme Corporation ($16.52) |
| 2017 | $249.73 | 4 | Merck Sharp & Dohme Corporation ($125.00) |
All Payment Transactions
32 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/19/2023 | Ipsen Biopharmaceuticals, Inc | Tazverik (Drug) | Food and Beverage | In-kind items and services | $25.30 | General |
| Category: Oncology | ||||||
| 10/17/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $17.15 | General |
| Category: Hematology | ||||||
| 01/03/2023 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $20.91 | General |
| Category: Oncology | ||||||
| 10/24/2022 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $15.48 | General |
| Category: Hematology | ||||||
| 10/20/2022 | Amgen Inc. | Kyprolis (Drug) | Food and Beverage | In-kind items and services | $17.14 | General |
| Category: Oncology | ||||||
| 10/19/2022 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $16.99 | General |
| Category: Oncology | ||||||
| 10/18/2022 | Genentech USA, Inc. | Alecensa (Biological), TECENTRIQ, ROZLYTREK | Food and Beverage | In-kind items and services | $23.70 | General |
| Category: BioOncology | ||||||
| 09/28/2022 | Incyte Corporation | JAKAFI (Drug), PEMAZYRE | Food and Beverage | Cash or cash equivalent | $22.00 | General |
| Category: Hematology/Oncology | ||||||
| 07/27/2022 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $25.10 | General |
| Category: Oncology | ||||||
| 06/30/2022 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $12.42 | General |
| Category: Oncology | ||||||
| 05/13/2022 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: Oncology | ||||||
| 05/12/2022 | Genentech USA, Inc. | GAZYVA (Biological), Alecensa, TECENTRIQ | Food and Beverage | In-kind items and services | $21.83 | General |
| Category: BioOncology | ||||||
| 05/10/2022 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $13.19 | General |
| Category: Oncology | ||||||
| 05/09/2022 | Incyte Corporation | JAKAFI (Drug), PEMAZYRE, MONJUVI | Food and Beverage | Cash or cash equivalent | $18.00 | General |
| Category: Hematology/Oncology | ||||||
| 05/09/2022 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $16.76 | General |
| Category: ONCOLOGY | ||||||
| 12/28/2021 | Incyte Corporation | — | Education | Cash or cash equivalent | $67.99 | General |
| 12/22/2021 | Incyte Corporation | JAKAFI (Drug), PEMAZYRE | Food and Beverage | Cash or cash equivalent | $12.69 | General |
| Category: Hematology/Oncology | ||||||
| 10/21/2021 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $16.79 | General |
| Category: ONCOLOGY | ||||||
| 05/14/2021 | Incyte Corporation | JAKAFI (Drug), PEMAZYRE | Food and Beverage | Cash or cash equivalent | $15.84 | General |
| Category: Hematology/Oncology | ||||||
| 05/14/2021 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $15.73 | General |
| Category: Oncology | ||||||
| 04/20/2021 | Genentech USA, Inc. | Alecensa (Biological), ROZLYTREK | Food and Beverage | In-kind items and services | $101.66 | General |
| Category: BioOncology | ||||||
| 11/19/2019 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ONCOLOGY | ||||||
| 10/21/2019 | Teva Pharmaceuticals USA, Inc. | BENDEKA (Drug) | Food and Beverage | In-kind items and services | $15.16 | General |
| Category: Oncology | ||||||
| 09/27/2019 | Lexicon Pharmaceuticals, Inc. | Xermelo (Drug) | Food and Beverage | In-kind items and services | $15.36 | General |
| Category: Carcinoid Syndrome Diarrhea | ||||||
| 06/12/2019 | Janssen Biotech, Inc. | ZYTIGA (Drug) | Food and Beverage | In-kind items and services | $11.09 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 243 | 599 | $216,805 | $45,336 |
| 2022 | 4 | 282 | 702 | $228,161 | $56,962 |
| 2021 | 5 | 318 | 757 | $230,036 | $72,338 |
| 2020 | 5 | 339 | 953 | $282,156 | $87,128 |
Total Patients
1,182
Total Services
3,011
Medicare Billing
$261,765
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 160 | 497 | $168,980 | $35,211 | 20.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 41 | 41 | $27,183 | $5,589 | 20.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 21 | 29 | $13,282 | $2,960 | 22.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 21 | 32 | $7,360 | $1,576 | 21.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 174 | 558 | $166,920 | $41,580 | 24.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 53 | 53 | $32,739 | $7,671 | 23.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 28 | 49 | $20,618 | $5,531 | 26.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 27 | 42 | $7,884 | $2,181 | 27.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 170 | 531 | $155,484 | $42,529 | 27.4% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2021 | 25 | 85 | $13,600 | $13,600 | 100.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 58 | 58 | $35,766 | $8,489 | 23.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 35 | 44 | $18,040 | $5,469 | 30.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 30 | 39 | $7,146 | $2,252 | 31.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 156 | 543 | $169,644 | $38,256 | 22.6% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2020 | 37 | 208 | $33,280 | $33,014 | 99.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 42 | 42 | $26,742 | $6,063 | 22.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 50 | 87 | $29,580 | $4,235 | 14.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 26 | 34 | $15,044 | $3,381 | 22.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 28 | 39 | $7,866 | $2,180 | 27.7% |
About Dr. Robert Hirsch, MD
Dr. Robert Hirsch, MD is a Hematology & Oncology healthcare provider based in Aventura, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1093709669.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Hirsch, MD has received a total of $985.48 in payments from pharmaceutical and medical device companies, with $63.36 received in 2023. These payments were reported across 32 transactions from 14 companies. The most common payment nature is "Food and Beverage" ($917.49).
As a Medicare-enrolled provider, Hirsch has provided services to 1,182 Medicare beneficiaries, totaling 3,011 services with total Medicare billing of $261,765. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Aventura, FL
- Active Since 09/09/2005
- Last Updated 03/19/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1093709669
Products in Payments
- KEYTRUDA (Biological) $141.52
- Alecensa (Biological) $125.36
- MEKINIST (Drug) $125.00
- TECENTRIQ (Biological) $115.90
- JAKAFI (Drug) $68.53
- ERLEADA (Drug) $46.01
- PROMACTA (Drug) $33.55
- Pomalyst (Drug) $32.63
- GAZYVA (Biological) $30.66
- DARZALEX (Biological) $29.41
- Tazverik (Drug) $25.30
- Revlimid (Drug) $23.31
- CALQUENCE (Drug) $18.60
- Kyprolis (Drug) $17.14
- ADCETRIS (Biological) $15.73
- Xermelo (Drug) $15.36
- BENDEKA (Drug) $15.16
- INJECTAFER (Drug) $14.04
- Xospata (Drug) $13.19
- ZYTIGA (Drug) $11.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Aventura
Alejandra Del Toro, M.d, M.D
Hematology & Oncology — Payments: $18,346
Hematology & Oncology $18,346
Miss. Jennifer Cudris Maldonado, M.d, M.D
Hematology & Oncology — Payments: $12,626
Hematology & Oncology $12,626
Gelenis Domingo, M.d, M.D
Hematology & Oncology — Payments: $5,908
Hematology & Oncology $5,908
Marc Saltzman, M.d, M.D
Hematology & Oncology — Payments: $2,747
Hematology & Oncology $2,747
Dr. Enrique Davila, Md, MD
Hematology & Oncology — Payments: $1,098
Hematology & Oncology $1,098
Dr. Jonathan Leslie, D.o, D.O
Hematology & Oncology — Payments: $25.31
Hematology & Oncology $25.31